Health Care & Life Sciences » Biotechnology | ADMA Biologics Inc.

ADMA Biologics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
29,084.70
21,851.70
16,809.10
15,305.10
44,607.60
22,754.90
Total Accounts Receivable
-
384.00
924.50
1,018.00
3,880.20
1,392.40
Inventories
1,669.10
1,708.80
3,445.80
5,020.10
12,628.20
18,616.20
Other Current Assets
298.70
143.60
111.00
313.90
2,050.70
1,766.20
Total Current Assets
31,052.40
24,088.00
21,290.40
21,657.10
63,166.60
44,529.60
Net Property, Plant & Equipment
765.30
2,840.70
2,397.00
2,000.80
30,466.90
30,115.70
Total Investments and Advances
-
-
-
-
4,000.00
4,000
Intangible Assets
-
-
-
-
8,378.90
7,533.90
Other Assets
162.20
298.80
27.20
27.20
2,006.50
2,697.20
Total Assets
31,979.90
27,227.50
23,714.50
23,685.10
108,018.80
88,876.50
ST Debt & Current Portion LT Debt
12.70
13.80
15.10
6,127.70
-
Accounts Payable
2,709.50
1,779.20
2,087.90
2,564.70
5,920.90
Other Current Liabilities
935.70
2,404.90
2,113.50
2,530.50
3,519.30
Total Current Liabilities
3,657.80
4,197.90
4,216.50
11,222.90
9,440.20
Long-Term Debt
5,063.00
14,956.20
15,715.50
14,131.30
42,970.90
Other Liabilities
1,685.80
2,064.80
2,961.50
2,788.20
15,275.00
Total Liabilities
10,406.60
21,218.80
22,893.50
28,142.30
67,686.10
Common Equity (Total)
21,573.40
6,008.70
821.00
4,457.30
40,332.80
Total Shareholders' Equity
21,573.40
6,008.70
821.00
4,457.30
40,332.80
Total Equity
21,573.40
6,008.70
821.00
4,457.30
40,332.80
Liabilities & Shareholders' Equity
31,979.90
27,227.50
23,714.50
23,685.10
108,018.80

About ADMA Biologics

View Profile
Address
465 State Route 17 South
Ramsey New Jersey 07446
United States
Employees -
Website http://www.admabiologics.com
Updated 07/08/2019
ADMA Biologics, Inc. is a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. It operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate.